PYRAZINAMIDE (Z), 150mg, disp. tab., bulk

STD DORAPYRZ1TD3

Valid Article

Former Code(s): DORAPYRZ1T3
Article is intended to be used with children (<12 years) ONLY.
6.2.5 - Antituberculosis medicines
Classification of the medicines in groups and subgroups according to their therapeutic use. The classification used by MSF is based on the WHO Model List of Essential Medicines.
J04AK01
Anatomical Therapeutic Chemical Classification according to WHOCC
The order of this product needs to be justified and is only acceptable under certain conditions.
Thermosensitive codes are defined for storage and transportation temperature requirements of the products.
OC subscriptions: included in supply or field order tools (e.g. UniField)
SC subscriptions: included in supply or field tools
OC validations: approved for procurement and use by an OC for international or local orders specifying context and activity in Medical Standard Lists (MSL)

This combination does not exist.

Add article to list

   

Add Kit To Wishlist

   

PYRAZINAMIDE (Z)

Therapeutic Action

Antituberculosis bactericide

Indications

Drug-Resistant Tuberculosis (DR-TB), in combination with other TB medicines

Drug-Sensitive Tuberculosis (DS-TB)

Instructions for use

The 150 mg dispersible tablet is intended for paediatric use. To be dispersed in 10 ml water.

When pyrazinamide is used in association with other TB medicines, fixed-dose combinations (FDC) are available:

  • E 275mg / H 75mg / Z 400mg / R 150mg, tab., blister
  • H 50mg / Z 150mg / R 75mg, disp. tab., blister

Blister packaging is the packaging of choice for antituberculosis medicines due to the unstable nature of some of them when exposed to higher temperatures and humidity.

Bulk packaging (hospital packs) should only be used in special circumstances or in case of unexpected problems in availability of the blister presentation.

The quantity to be ordered is calculated per tablet, not per blister.

Storage

Below 25°C ‐ Protect from sunlight ‐ Protect from humidity